fludarabine has been researched along with curcumin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Everett, PC; Lerner, A; Makkinje, A; Meyers, JA; Rabbi, M | 1 |
| Bartholomé, K; Buchner, M; Burger, M; Chevalier, N; Dierks, C; Fuchs, S; Gribben, JG; Jumaa, H; Pfeifer, D; Prinz, G; Timmer, J; Vallat, L; Veelken, H; Zirlik, K | 1 |
1 trial(s) available for fludarabine and curcumin
| Article | Year |
|---|---|
Preclinical assessment of curcumin as a potential therapy for B-CLL.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Curcumin; Cyclic Nucleotide Phosphodiesterases, Type 4; Dexamethasone; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; NF-kappa B; NF-kappaB-Inducing Kinase; PPAR gamma; Protein Serine-Threonine Kinases; Rolipram; Signal Transduction; Tumor Cells, Cultured; Vidarabine; Vincristine | 2007 |
1 other study(ies) available for fludarabine and curcumin
| Article | Year |
|---|---|
Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B-Lymphocytes; Caspase 3; Cell Line, Tumor; Curcumin; Gene Expression Profiling; Humans; Immunoglobulin Variable Region; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Neoplasm Staging; Oxazines; Phosphorylation; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Pyridines; Syk Kinase; Vidarabine | 2009 |